Federal judge allows Nexium reverse payment patent settlement suit to proceed
Last week, a federal judge in Massachusetts largely denied a series of motions seeking dismissal of various ‘pay-for-delay’ claims brought by direct and indirect purchasers involving AstraZeneca’s acid reflux drug Nexium. Although certain federal and state claims were trimmed on statute of limitation grounds, US district judge William Young let stand the core claims of the suit based on the alleged continuing harm flowing from the agreements.
This ruling comes just months after the Supreme Court’s long-awaited decision in FTC v Actavis and is one of the first times a court has applied the rule of reason analysis as articulated by the court. Significantly, in his ruling Young adopted a view strongly urged by the FTC that so-called ‘No-AG’ provisions can be viewed as ‘reverse payments’.
The agreements at issue settled patent litigation filed by AstraZeneca in November 2005 after Ranbaxy notified AstraZeneca that it intended to market generic versions of Nexium. As part of its Abbreviated New Drug Application (ANDA), Ranbaxy included a so-called ‘Paragraph IV’ certification that the commercial manufacture, use and/or sale of any generic Nexium product would not infringe any of AstraZeneca’s valid patents. The Ranbaxy ANDA filing was followed soon after by ANDA filings by Teva and Dr Reddy’s and additional patent suits filed by AstraZeneca against each…
If you are registered and logged in to the site, click on the link below to read the rest of the Hogan Lovells briefing. If not, please register or sign in with your details below.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
Companies in the federal supply chain have an opportunity to prepare for the expansion of government’s anti-human-trafficking rules
This update highlights the salient aspects of the proposed rules and the requirements that are likely to be of most interest to contractors.
Companies should assess their business operations and relationships in Ukraine.
Analysis from The Lawyer
When a firm shouts loudly about a landmark merger, as SJ Berwin did when it joined forces with King & Wood Mallesons, departures are always likely to come under the spotlight.
The Lawyer’s latest Top 50 litigation firms list shows that business for dispute specialists is roaring along while new in-depth detail reveals the winning strategies